<p>Walleye Capital LLC 在最近向證券交易委員會（SEC）提交的 13F 文件中披露，在第四季度收購了 Rhythm Pharmaceuticals, Inc.（NASDAQ:RYTM - 免費報告）的新股份。這家機構投資者收購了 144,342 股該公司的股票，價值約為 8,080,000 美元。Walleye Capital LLC 在最近的報告期末持有 Rhythm Pharmaceuticals 0.23% 的股份。</p>
<p>獲取 <strong>Rhythm Pharmaceuticals</strong> 警報：</p>
<ul>
<li>7 只將推動減肥藥市場的股票</li>
</ul>
<p>其他幾家機構投資者也調整了對該股票的持有。SRS Capital Advisors Inc. 在第四季度將其在 Rhythm Pharmaceuticals 的持股增加了 740.7%。SRS Capital Advisors Inc. 現在擁有 454 股該公司的股票，價值 25,000 美元，此前在上個季度購買了額外的 400 股。Raleigh Capital Management Inc. 在第四季度以約 28,000 美元的價格購買了 Rhythm Pharmaceuticals 的新股份。SBI Securities Co. Ltd. 在第四季度以約 37,000 美元的價格購買了 Rhythm Pharmaceuticals 的新股份。R Squared Ltd 在第四季度以約 44,000 美元的價格購買了 Rhythm Pharmaceuticals 的新股份。最後，KBC Group NV 在第四季度將其在 Rhythm Pharmaceuticals 的持股增加了 78.2%。KBC Group NV 現在擁有 2,251 股該公司的股票，價值 126,000 美元，此前在該期間內收購了額外的 988 股。</p>
<h2>Rhythm Pharmaceuticals 股票上漲 3.2%</h2>
<p>Rhythm Pharmaceuticals 股票週三開盤價為 62.09 美元。該公司的市值為 39.3 億美元，市盈率為 -14.34，貝塔值為 2.32。該公司的 50 日移動平均線為 54.55 美元，200 日移動平均線為 55.43 美元。Rhythm Pharmaceuticals, Inc. 的 12 個月低點為 35.17 美元，12 個月高點為 68.58 美元。</p>
<ul>
<li>2 家生物科技公司有前景的減肥藥即將推出</li>
</ul>
<p>Rhythm Pharmaceuticals（NASDAQ:RYTM - 獲取免費報告）最近在 2 月 26 日星期三發佈了季度財報。該公司報告的每股收益為（0.72）美元，低於分析師一致預期的（0.69）美元，差額為（0.03）美元。Rhythm Pharmaceuticals 的股本回報率為 -367.36%，淨利潤率為 -230.07%。該公司本季度的收入為 4,183 萬美元，而分析師預期為 3,848 萬美元。股票分析師預計 Rhythm Pharmaceuticals, Inc. 在當前年度的每股收益將為 -4.32 美元。</p>
<h2>分析師升級和降級</h2>
<p>幾位分析師最近對該公司發表了看法。Stifel Nicolaus 在 3 月 5 日星期三的研究報告中開始覆蓋 Rhythm Pharmaceuticals。他們為該公司設定了 “買入” 評級和 78.00 美元的目標價。Wells Fargo &amp; Company 在 4 月 7 日星期一的報告中將 Rhythm Pharmaceuticals 的目標價從 80.00 美元上調至 91.00 美元，並給予該公司 “增持” 評級。Jefferies Financial Group 在 1 月 2 日星期四的研究報告中開始覆蓋 Rhythm Pharmaceuticals 的股票。他們為該公司發佈了 “買入” 評級和 80.00 美元的目標價。JMP Securities 在 12 月 23 日星期一的研究報告中重申了 “市場表現優於大盤” 的評級，併為 Rhythm Pharmaceuticals 的股票設定了 75.00 美元的目標價。最後，HC Wainwright 在 4 月 8 日星期二的報告中重申了 “買入” 評級，並將 Rhythm Pharmaceuticals 的目標價從 70.00 美元上調至 80.00 美元。根據 MarketBeat 的數據，十三位股票研究分析師對該股票給予了買入評級，目前該股票的平均評級為 “買入”，共識目標價為 74.92 美元。</p>
<p><strong>閲讀我們關於 Rhythm Pharmaceuticals 的最新股票分析</strong></p>
<h2>Rhythm Pharmaceuticals 的內部買賣</h2>
<p>在相關消息中，執行副總裁 Yann Mazabraud 於 3 月 14 日星期五出售了 75,000 股該股票，交易發生在平均價格為 51.48 美元，總交易額為 3,861,000.00 美元。出售完成後，該執行副總裁現在持有 40,370 股該公司的股票，價值 2,078,247.60 美元。這代表了他們持有股票的 65.01% 的減少。該交易已在與 SEC 的法律文件中披露，相關文件可在此鏈接查看。此外，首席財務官 Hunter C. Smith 於 2 月 4 日星期二出售了 1,678 股 Rhythm Pharmaceuticals 的股票。該股票以平均價格 59.43 美元出售，總交易額為 99,723.54 美元。交易完成後，首席財務官現在直接持有 101,186 股該公司股票，價值 6,013,483.98 美元。這代表了他們持有股票的 1.63% 的減少。該銷售的披露信息可以在這裏找到。在過去的九十天裏，內部人士出售了 146,641 股公司股票，價值 8,112,177 美元。當前 5.60% 的股票由內部人士持有。</p>
<h2>關於 Rhythm Pharmaceuticals</h2>
<p>（免費報告）</p>
<p>Rhythm Pharmaceuticals, Inc. 是一家商業階段的生物製藥公司，專注於罕見的神經內分泌疾病。該公司的主要產品候選藥物是 IMCIVREE（setmelanotide），用於治療促黑激素前體（POMC）、前蛋白轉化酶 subtilisin/kexin 類型 1、瘦素受體（LEPR）缺乏症肥胖，以及 Bardet-Biedl 綜合症和 Alström 綜合症。</p>
<h2>精選文章</h2>
<ul>
<li>五隻我們更看好的股票，勝過 Rhythm Pharmaceuticals</li>
<li>投資者最重要的沃倫·巴菲特股票：他自己的股票</li>
<li>當心 BigBear.ai：內部人士正在出售——你應該嗎？</li>
<li>經紀排名在股票選擇中的重要性</li>
<li>隨着網絡威脅環境的擴大，CrowdStrike 股票值得購買</li>
<li>股票分紅削減發生，你準備好了嗎？</li>
<li>國會！在關税引發的崩潰中，誰交易了什麼</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9UllUTQ?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9UllUTQ"/></p>
<p><em>此即時新聞提醒由敍事科學技術和 MarketBeat 的金融數據生成，旨在為讀者提供最快和最準確的報道。此故事在發佈前已由 MarketBeat 的編輯團隊審核。請將有關此故事的任何問題或評論發送至 contact@marketbeat.com.</em></p>
<h2>你現在應該投資 1,000 美元在 Rhythm Pharmaceuticals 嗎？</h2>
<p>在考慮 Rhythm Pharmaceuticals 之前，你需要聽聽這個。</p>
<p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已識別出五隻頂級分析師悄悄建議客户現在購買的股票，以便在更廣泛的市場注意到之前……而 Rhythm Pharmaceuticals 並不在名單上。</p>
<p>雖然 Rhythm Pharmaceuticals 目前在分析師中獲得了買入評級，但頂級分析師認為這五隻股票更值得購買。</p>
<p>在這裏查看這五隻股票</p>

RYTM

<p>Walleye Capital LLC 在第四季度收購了 144,342 股 Rhythm Pharmaceuticals, Inc.（納斯達克代碼：RYTM），價值約 808 萬美元，依據最近的 SEC 文件。其他機構投資者也增加了對該公司的持股。Rhythm Pharmaceuticals 的股票開盤價為 62.09 美元，市值為 39.3 億美元。該公司報告季度每股虧損 0.72 美元，未達到預期，但收入為 4183 萬美元。分析師維持 “買入” 評級，目標價共識為 74.92 美元</p>

<p>Walleye Capital LLC acquired a new stake in shares of Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM - Free Report) during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 144,342 shares of the company's stock, valued at approximately $8,080,000. Walleye Capital LLC owned 0.23% of Rhythm Pharmaceuticals at the end of the most recent reporting period.</p>
<div class="lb-trans"><p>Walleye Capital LLC 在最近向證券交易委員會（SEC）提交的 13F 文件中披露，在第四季度收購了 Rhythm Pharmaceuticals, Inc.（NASDAQ:RYTM - 免費報告）的新股份。這家機構投資者收購了 144,342 股該公司的股票，價值約為 8,080,000 美元。Walleye Capital LLC 在最近的報告期末持有 Rhythm Pharmaceuticals 0.23% 的股份。</p>
</div><p>Get <strong>Rhythm Pharmaceuticals</strong> alerts:</p>
<div class="lb-trans"><p>獲取 <strong>Rhythm Pharmaceuticals</strong> 警報：</p>
</div><ul>
<li>7 Stocks That Will Drive the Weight Loss Drugs Market</li>
</ul>
<div class="lb-trans"><ul>
<li>7 只將推動減肥藥市場的股票</li>
</ul>
</div><p>Several other institutional investors have also modified their holdings of the stock. SRS Capital Advisors Inc. grew its holdings in Rhythm Pharmaceuticals by 740.7% during the 4th quarter. SRS Capital Advisors Inc. now owns 454 shares of the company's stock valued at $25,000 after purchasing an additional 400 shares during the last quarter. Raleigh Capital Management Inc. bought a new position in shares of Rhythm Pharmaceuticals during the fourth quarter valued at approximately $28,000. SBI Securities Co. Ltd. purchased a new stake in shares of Rhythm Pharmaceuticals in the fourth quarter worth approximately $37,000. R Squared Ltd bought a new stake in shares of Rhythm Pharmaceuticals during the 4th quarter worth approximately $44,000. Finally, KBC Group NV boosted its holdings in Rhythm Pharmaceuticals by 78.2% during the 4th quarter. KBC Group NV now owns 2,251 shares of the company's stock valued at $126,000 after acquiring an additional 988 shares during the period.</p>
<div class="lb-trans"><p>其他幾家機構投資者也調整了對該股票的持有。SRS Capital Advisors Inc. 在第四季度將其在 Rhythm Pharmaceuticals 的持股增加了 740.7%。SRS Capital Advisors Inc. 現在擁有 454 股該公司的股票，價值 25,000 美元，此前在上個季度購買了額外的 400 股。Raleigh Capital Management Inc. 在第四季度以約 28,000 美元的價格購買了 Rhythm Pharmaceuticals 的新股份。SBI Securities Co. Ltd. 在第四季度以約 37,000 美元的價格購買了 Rhythm Pharmaceuticals 的新股份。R Squared Ltd 在第四季度以約 44,000 美元的價格購買了 Rhythm Pharmaceuticals 的新股份。最後，KBC Group NV 在第四季度將其在 Rhythm Pharmaceuticals 的持股增加了 78.2%。KBC Group NV 現在擁有 2,251 股該公司的股票，價值 126,000 美元，此前在該期間內收購了額外的 988 股。</p>
</div><h2>Rhythm Pharmaceuticals Stock Up 3.2 %</h2>
<div class="lb-trans"><h2>Rhythm Pharmaceuticals 股票上漲 3.2%</h2>
</div><p>Rhythm Pharmaceuticals stock opened at $62.09 on Wednesday. The firm has a market cap of $3.93 billion, a P/E ratio of -14.34 and a beta of 2.32. The business has a fifty day moving average of $54.55 and a two-hundred day moving average of $55.43. Rhythm Pharmaceuticals, Inc. has a twelve month low of $35.17 and a twelve month high of $68.58.</p>
<div class="lb-trans"><p>Rhythm Pharmaceuticals 股票週三開盤價為 62.09 美元。該公司的市值為 39.3 億美元，市盈率為 -14.34，貝塔值為 2.32。該公司的 50 日移動平均線為 54.55 美元，200 日移動平均線為 55.43 美元。Rhythm Pharmaceuticals, Inc. 的 12 個月低點為 35.17 美元，12 個月高點為 68.58 美元。</p>
</div><ul>
<li>2 biotechs with promising weight-loss drugs coming</li>
</ul>
<div class="lb-trans"><ul>
<li>2 家生物科技公司有前景的減肥藥即將推出</li>
</ul>
</div><p>Rhythm Pharmaceuticals (NASDAQ:RYTM - Get Free Report) last issued its quarterly earnings data on Wednesday, February 26th. The company reported ($0.72) earnings per share for the quarter, missing analysts' consensus estimates of ($0.69) by ($0.03). Rhythm Pharmaceuticals had a negative return on equity of 367.36% and a negative net margin of 230.07%. The company had revenue of $41.83 million for the quarter, compared to analysts' expectations of $38.48 million. Equities analysts expect that Rhythm Pharmaceuticals, Inc. will post -4.32 earnings per share for the current year.</p>
<div class="lb-trans"><p>Rhythm Pharmaceuticals（NASDAQ:RYTM - 獲取免費報告）最近在 2 月 26 日星期三發佈了季度財報。該公司報告的每股收益為（0.72）美元，低於分析師一致預期的（0.69）美元，差額為（0.03）美元。Rhythm Pharmaceuticals 的股本回報率為 -367.36%，淨利潤率為 -230.07%。該公司本季度的收入為 4,183 萬美元，而分析師預期為 3,848 萬美元。股票分析師預計 Rhythm Pharmaceuticals, Inc. 在當前年度的每股收益將為 -4.32 美元。</p>
</div><h2>Analyst Upgrades and Downgrades</h2>
<div class="lb-trans"><h2>分析師升級和降級</h2>
</div><p>Several analysts have recently weighed in on the company. Stifel Nicolaus started coverage on Rhythm Pharmaceuticals in a research report on Wednesday, March 5th. They set a &#34;buy&#34; rating and a $78.00 target price for the company. Wells Fargo &amp; Company lifted their price objective on shares of Rhythm Pharmaceuticals from $80.00 to $91.00 and gave the company an &#34;overweight&#34; rating in a report on Monday, April 7th. Jefferies Financial Group began coverage on shares of Rhythm Pharmaceuticals in a research report on Thursday, January 2nd. They issued a &#34;buy&#34; rating and a $80.00 price objective for the company. JMP Securities reaffirmed a &#34;market outperform&#34; rating and set a $75.00 target price on shares of Rhythm Pharmaceuticals in a research report on Monday, December 23rd. Finally, HC Wainwright reiterated a &#34;buy&#34; rating and issued a $80.00 price target (up previously from $70.00) on shares of Rhythm Pharmaceuticals in a report on Tuesday, April 8th. Thirteen equities research analysts have rated the stock with a buy rating, According to data from MarketBeat, the stock currently has an average rating of &#34;Buy&#34; and a consensus price target of $74.92.</p>
<div class="lb-trans"><p>幾位分析師最近對該公司發表了看法。Stifel Nicolaus 在 3 月 5 日星期三的研究報告中開始覆蓋 Rhythm Pharmaceuticals。他們為該公司設定了 “買入” 評級和 78.00 美元的目標價。Wells Fargo &amp; Company 在 4 月 7 日星期一的報告中將 Rhythm Pharmaceuticals 的目標價從 80.00 美元上調至 91.00 美元，並給予該公司 “增持” 評級。Jefferies Financial Group 在 1 月 2 日星期四的研究報告中開始覆蓋 Rhythm Pharmaceuticals 的股票。他們為該公司發佈了 “買入” 評級和 80.00 美元的目標價。JMP Securities 在 12 月 23 日星期一的研究報告中重申了 “市場表現優於大盤” 的評級，併為 Rhythm Pharmaceuticals 的股票設定了 75.00 美元的目標價。最後，HC Wainwright 在 4 月 8 日星期二的報告中重申了 “買入” 評級，並將 Rhythm Pharmaceuticals 的目標價從 70.00 美元上調至 80.00 美元。根據 MarketBeat 的數據，十三位股票研究分析師對該股票給予了買入評級，目前該股票的平均評級為 “買入”，共識目標價為 74.92 美元。</p>
</div><p><strong>Read Our Latest Stock Analysis on Rhythm Pharmaceuticals</strong></p>
<div class="lb-trans"><p><strong>閲讀我們關於 Rhythm Pharmaceuticals 的最新股票分析</strong></p>
</div><h2>Insider Buying and Selling at Rhythm Pharmaceuticals</h2>
<div class="lb-trans"><h2>Rhythm Pharmaceuticals 的內部買賣</h2>
</div><p>In related news, EVP Yann Mazabraud sold 75,000 shares of the stock in a transaction that occurred on Friday, March 14th. The shares were sold at an average price of $51.48, for a total transaction of $3,861,000.00. Following the completion of the sale, the executive vice president now owns 40,370 shares of the company's stock, valued at $2,078,247.60. This represents a 65.01 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, CFO Hunter C. Smith sold 1,678 shares of Rhythm Pharmaceuticals stock in a transaction on Tuesday, February 4th. The stock was sold at an average price of $59.43, for a total transaction of $99,723.54. Following the completion of the transaction, the chief financial officer now directly owns 101,186 shares in the company, valued at $6,013,483.98. This represents a 1.63 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 146,641 shares of company stock valued at $8,112,177. 5.60% of the stock is currently owned by insiders.</p>
<div class="lb-trans"><p>在相關消息中，執行副總裁 Yann Mazabraud 於 3 月 14 日星期五出售了 75,000 股該股票，交易發生在平均價格為 51.48 美元，總交易額為 3,861,000.00 美元。出售完成後，該執行副總裁現在持有 40,370 股該公司的股票，價值 2,078,247.60 美元。這代表了他們持有股票的 65.01% 的減少。該交易已在與 SEC 的法律文件中披露，相關文件可在此鏈接查看。此外，首席財務官 Hunter C. Smith 於 2 月 4 日星期二出售了 1,678 股 Rhythm Pharmaceuticals 的股票。該股票以平均價格 59.43 美元出售，總交易額為 99,723.54 美元。交易完成後，首席財務官現在直接持有 101,186 股該公司股票，價值 6,013,483.98 美元。這代表了他們持有股票的 1.63% 的減少。該銷售的披露信息可以在這裏找到。在過去的九十天裏，內部人士出售了 146,641 股公司股票，價值 8,112,177 美元。當前 5.60% 的股票由內部人士持有。</p>
</div><h2>About Rhythm Pharmaceuticals</h2>
<div class="lb-trans"><h2>關於 Rhythm Pharmaceuticals</h2>
</div><p>(Free Report)</p>
<div class="lb-trans"><p>（免費報告）</p>
</div><p>Rhythm Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on the rare neuroendocrine diseases. The company's lead product candidate is IMCIVREE (setmelanotide), a rare melanocortin-4 receptor for the treatment of pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1, leptin receptor (LEPR) deficiency obesity, and Bardet-Biedl and Alström syndrome.</p>
<div class="lb-trans"><p>Rhythm Pharmaceuticals, Inc. 是一家商業階段的生物製藥公司，專注於罕見的神經內分泌疾病。該公司的主要產品候選藥物是 IMCIVREE（setmelanotide），用於治療促黑激素前體（POMC）、前蛋白轉化酶 subtilisin/kexin 類型 1、瘦素受體（LEPR）缺乏症肥胖，以及 Bardet-Biedl 綜合症和 Alström 綜合症。</p>
</div><h2>Featured Articles</h2>
<div class="lb-trans"><h2>精選文章</h2>
</div><ul>
<li>Five stocks we like better than Rhythm Pharmaceuticals</li>
<li>The Most Important Warren Buffett Stock for Investors: His Own</li>
<li>Beware of BigBear.ai: Insiders Are Selling—Should You?</li>
<li>The Significance of Brokerage Rankings in Stock Selection</li>
<li>CrowdStrike Stock is a Buy as Cyberthreat Environment Expands</li>
<li>Stock Dividend Cuts Happen Are You Ready?</li>
<li>Congress! Who Traded What During the Tariff-Induced Meltdown</li>
</ul>
<div class="lb-trans"><ul>
<li>五隻我們更看好的股票，勝過 Rhythm Pharmaceuticals</li>
<li>投資者最重要的沃倫·巴菲特股票：他自己的股票</li>
<li>當心 BigBear.ai：內部人士正在出售——你應該嗎？</li>
<li>經紀排名在股票選擇中的重要性</li>
<li>隨着網絡威脅環境的擴大，CrowdStrike 股票值得購買</li>
<li>股票分紅削減發生，你準備好了嗎？</li>
<li>國會！在關税引發的崩潰中，誰交易了什麼</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9UllUTQ" alt="" original-src="https://www.marketbeat.com/scripts/SECFilingChart.ashx?Prefix=NASDAQ&amp;Symbol=RYTM"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即時新聞提醒由敍事科學技術和 MarketBeat 的金融數據生成，旨在為讀者提供最快和最準確的報道。此故事在發佈前已由 MarketBeat 的編輯團隊審核。請將有關此故事的任何問題或評論發送至 contact@marketbeat.com.</em></p>
</div><h2>Should You Invest $1,000 in Rhythm Pharmaceuticals Right Now?</h2>
<div class="lb-trans"><h2>你現在應該投資 1,000 美元在 Rhythm Pharmaceuticals 嗎？</h2>
</div><p>Before you consider Rhythm Pharmaceuticals, you'll want to hear this.</p>
<div class="lb-trans"><p>在考慮 Rhythm Pharmaceuticals 之前，你需要聽聽這個。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Rhythm Pharmaceuticals wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已識別出五隻頂級分析師悄悄建議客户現在購買的股票，以便在更廣泛的市場注意到之前……而 Rhythm Pharmaceuticals 並不在名單上。</p>
</div><p>While Rhythm Pharmaceuticals currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>雖然 Rhythm Pharmaceuticals 目前在分析師中獲得了買入評級，但頂級分析師認為這五隻股票更值得購買。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在這裏查看這五隻股票</p>
</div>

Walleye Capital LLC 購入了 144,342 股 Rhythm Pharmaceuticals, Inc.（NASDAQ:RYTM）的股票